Literature DB >> 18272958

The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney.

J A Phipps1, E P Feener.   

Abstract

Diabetic retinopathy and diabetic nephropathy are common microvascular complications of diabetes. The kallikrein-kinin system (KKS) has been implicated in the development of both conditions, and, in particular, bradykinin and its receptors have been shown to exert angiogenic and proinflammatory actions. Several of the key processes that underlie the development of diabetic retinopathy, such as increased vascular permeability, edema, neovascularization, and inflammatory changes, have been associated with the KKS, and recent work has shown that components of the KKS, including plasma kallikrein, factor XIIa, and high-molecular-weight kininogen, are present in the vitreous of people with diabetic retinopathy. The role of the KKS in the development of diabetic nephropathy is controversial, with both adverse and protective effects of bradykinin and its receptors reported. The review examines the role of the KKS in pathways central to the development of diabetic retinopathy and compares this with reported actions of this system in diabetic nephropathy. The possibility of therapeutic intervention targeting bradykinin and its receptors as treatment for diabetic microvascular conditions is considered.

Entities:  

Mesh:

Year:  2008        PMID: 18272958     DOI: 10.1038/ki.2008.9

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  16 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction.

Authors:  Luis F Quintana; Josep M Campistol; Maria P Alcolea; Elisenda Bañon-Maneus; Amandaé Sol-González; Pedro R Cutillas
Journal:  Mol Cell Proteomics       Date:  2009-04-07       Impact factor: 5.911

3.  Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Authors:  Ashay D Bhatwadekar; Viral S Kansara; Thomas A Ciulla
Journal:  Expert Opin Investig Drugs       Date:  2020-01-31       Impact factor: 6.206

Review 4.  Diabetic retinopathy: Breaking the barrier.

Authors:  Randa S Eshaq; Alaa M Z Aldalati; J Steven Alexander; Norman R Harris
Journal:  Pathophysiology       Date:  2017-07-12

5.  Expression, distribution and function of kinin B1 receptor in the rat diabetic retina.

Authors:  Soumaya Hachana; Menakshi Bhat; Jacques Sénécal; Frédéric Huppé-Gourgues; Réjean Couture; Elvire Vaucher
Journal:  Br J Pharmacol       Date:  2018-02-13       Impact factor: 8.739

6.  Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms.

Authors:  Kannikar Wongdee; Narattaphol Charoenphandhu
Journal:  World J Diabetes       Date:  2011-03-15

7.  Exclusion of aldose reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease.

Authors:  Ivy S Samuels; Chieh-Allen Lee; J Mark Petrash; Neal S Peachey; Timothy S Kern
Journal:  Vis Neurosci       Date:  2012-10-29       Impact factor: 3.241

8.  Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.

Authors:  Joanna A Phipps; Allen C Clermont; Sukanto Sinha; Tamie J Chilcote; Sven-Erik Bursell; Edward P Feener
Journal:  Hypertension       Date:  2009-01-05       Impact factor: 10.190

9.  Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.

Authors:  Allen Clermont; Tamie J Chilcote; Takeshi Kita; Jia Liu; Priscilla Riva; Sukanto Sinha; Edward P Feener
Journal:  Diabetes       Date:  2011-03-28       Impact factor: 9.461

10.  Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats.

Authors:  Mylène Pouliot; Sébastien Talbot; Jacques Sénécal; Florence Dotigny; Elvire Vaucher; Réjean Couture
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.